| Identification | Back Directory | [Name]
METFORMIN-D6, HYDROCHLORIDE | [CAS]
1185166-01-1 | [Synonyms]
Diabetosan-d6
Metiguanide-d6
Diabex-d6, Glucophage-d6
METFORMIN-D6, HYDROCHLORIDE
[2H6]-Metformin hydrochloride
Metformin-(dimethyl-d6) hydrochloride
1,1-Di(methyl-d3)biguanide hydrochloride
N,N-Dimethylimidodicarbonimidic Diamide-d6, Hydrochloride | [EINECS(EC#)]
604-604-1 | [Molecular Formula]
C4H6ClD6N5 | [MDL Number]
MFCD06658649 | [MOL File]
1185166-01-1.mol | [Molecular Weight]
171.662 |
| Chemical Properties | Back Directory | [Appearance]
White Crystalline Solid | [Melting point ]
215-218°C | [storage temp. ]
-20°C Freezer | [solubility ]
Aqueous Acid (Slightly), DMSO (Slightly), Methanol (Slightly) | [form ]
neat | [color ]
White to Off-White | [InChI]
InChI=1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H/i1D3;/hD3 | [InChIKey]
OETHQSJEHLVLGH-MIOFBDNISA-N | [SMILES]
N([2H])([2H])C(=N)N([2H])C(=N)N(C)C([2H])([2H])[2H].[H]Cl |
| Hazard Information | Back Directory | [Chemical Properties]
White Crystalline Solid | [Uses]
An oral hypoglycemic agent | [Description]
Metformin-d6 is intended for use as an internal standard for the quantification of metformin (Item No. 13118) by GC- or LC-MS. Metformin is a biguanide with diverse biological activities.1,2,3,4 Metformin (250 mg/kg, i.p.) increases hepatic AMPK activity and reduces blood glucose by more than 50% in a liver kinase B1-dependent manner in mice fed normal and high-fat diets, respectively, and reduces blood glucose by 40% in ob/ob mice.2 It reduces weight gain, hepatic lipid droplet content, and total cholesterol, LDL cholesterol, and triglyceride levels in the plasma of diet-induced obese mice when administered at doses of 10 or 50 mg/kg per day.4 It also reverses increased hepatic triglyceride and apolipoprotein A5 levels, as well as hepatic steatosis, in a dose-dependent manner in an ob/ob mouse model of non-alcoholic fatty liver disease (NAFLD).5 Metformin (250 mg/kg) reduces tumor growth in an HCT116 p53-\- human colon cancer mouse xenograft model, but has no effect on HCT116 p53-\- tumors overexpressing recombinant S. cerevisiae Ndi1 NADH dehydrogenase, a single-subunit ortholog of the multi-subunit mammalian mitochondrial complex I.3 Formulations containing metformin have been used in the treatment of type 2 diabetes. | [IC 50]
AMPK | [References]
[1] BENOIT VIOLLET. Cellular and molecular mechanisms of metformin: an overview.[J]. Clinical science, 2012, 122 6: 253-270. DOI: 10.1042/cs20110386
[2] REUBEN J. SHAW. The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin[J]. Science, 2005, 310 5754. DOI: 10.1126/science.1120781
[3] WILLIAM W WHEATON. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis.[J]. eLife, 2014: e02242. DOI: 10.7554/elife.02242
[4] EUN KYUNG KIM. Metformin Prevents Fatty Liver and Improves Balance of White/Brown Adipose in an Obesity Mouse Model by Inducing FGF21[J]. Mediators of Inflammation, 2016, 42 1. DOI: 10.1155/2016/5813030
[5] MIN-JIE LIN. Metformin improves nonalcoholic fatty liver disease in obese mice via down-regulation of apolipoprotein A5 as part of the AMPK/LXRα signaling pathway.[J]. Oncotarget, 2017, 8 65: 108802-108809. DOI: 10.18632/oncotarget.22163 |
|
|